Large Cell Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Large Cell Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of the DLL3-targeting radiopharmaceutical [212Pb]Pb-DOTAM-MAM279 (MP0712) in small cell lung cancer and other DLL…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors [Phase 2]
Phase 2 clinical trial evaluating the IDH2 inhibitor enasidenib (Idhifa) in IDH2-mutated malignant sinonasal and skull base tumors is curren…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Study of FZ-AD005 in Patients With Advanced Solid Tumors [Phase 1]
This is a Phase 1 study evaluating FZ-AD005 in adults with advanced solid tumors, including small cell lung cancer and large cell neuroendoc…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors [Phase 2]
Phase 2 trial evaluating cabozantinib (XL184) in combination with nivolumab and ipilimumab for poorly differentiated neuroendocrine tumors; …
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]
Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma [NA]
Clinical trial evaluating sequencing-based stratification for frontline treatment in high-grade neuroendocrine carcinoma has completed and r…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update for rovalpituzumab tesirine in DL3-expressing advanced solid tumors shows termination with results posted.